AJO

Audio Journal of Hematologic Malignancy Special Edition 2005

Reporting from:
- Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego
- Lymphoma: The Next Questions, April 8-9, 2005, Fort Lauderdale
- Journal of Clinical Oncology

In this edition:

The newer the better, so they say. But not this time, as we hear from Tony Green. He was looking into the treatment of essential thrombocythemia with the new agent, anagrelide. His group has discovered that superiority lies with the old treatment hydroxyurea.

Where can we go when imatinib stops working? Charles Sawyers is lighting the way for patients with chronic myeloid leukemia with the targeted therapy BMS 354 825.

Another reason has emerged why imatinib may not be the end of the road for patients with chronic myeloid leukemia who have become resistant. Francis Giles discusses the option of using the new agent AMN 107, which targets the BCR-ABL molecule in a new way.

Current proven treatment for multiple myeloma is still single agent dexamethozone, but is there scope for other therapies to be used up-front? S. Vincent Rajkumar has been working on two trials: one with thalidomide, and the other using a new drug lenalidomide.

Click here for more.

Similar Interviews

  • Hematologic Malignancy
  • Audio Journal of Hematologic Malignancy Volume 2 Number 1 Reporting from: American Society of Hematology Meeting, Philadelphia, December 6-10,

  • Audio Journal of Oncology - Prostate Cancer Special Edition 2005
  • Reporting from: - 2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida In this edition: Will they or won’t they

  • Audio Journal of Gastrointestinal Cancer Special Edition 2005
  • Reporting from: - Gastrointestinal Cancers Symposium, January 27-29, 2005, Hollywood, Florida In this edition: Bruce Giantonio and Robert Mayer discuss the Eastern Cooperative

    Post a comment

    Subscribe to Audio Medica Podcast